Organon & Co. (NYSE:OGN) Reaches New 1-Year Low – Here’s What Happened

Organon & Co. (NYSE:OGN)’s share price reached a new 52-week low on Monday . The stock traded as low as $5.76 and last traded at $5.7650, with a volume of 620674 shares changing hands. The stock had previously closed at $5.84.

Wall Street Analyst Weigh In

OGN has been the subject of several research reports. Zacks Research lowered shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Barclays raised their price target on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. Finally, Wall Street Zen cut Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $8.50.

Organon & Co. Price Performance

The firm has a market capitalization of $1.60 billion, a P/E ratio of 8.64, a PEG ratio of 0.53 and a beta of 0.60. The business’s 50-day simple moving average is $7.34 and its 200 day simple moving average is $7.95. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.52 billion. During the same quarter in the previous year, the firm posted $0.90 earnings per share. The company’s revenue was down 5.3% compared to the same quarter last year. Sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were paid a $0.02 dividend. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 annualized dividend and a yield of 1.3%. Organon & Co.’s payout ratio is currently 11.27%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OGN. Foster Dykema Cabot & Partners LLC bought a new position in shares of Organon & Co. during the third quarter valued at about $29,000. Farther Finance Advisors LLC lifted its stake in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after acquiring an additional 2,033 shares during the last quarter. Rothschild Investment LLC boosted its holdings in Organon & Co. by 73.1% during the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock valued at $42,000 after acquiring an additional 1,646 shares during the period. Eurizon Capital SGR S.p.A. purchased a new stake in Organon & Co. during the 4th quarter valued at about $44,000. Finally, Kestra Advisory Services LLC bought a new position in Organon & Co. during the 4th quarter worth approximately $47,000. 77.43% of the stock is owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.